Latest news with #AbbottLaboratories
Yahoo
2 days ago
- Business
- Yahoo
Top Research Reports for Meta Platforms, Palantir & Abbott
Friday, June 20, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Palantir Technologies Inc. (PLTR) and Abbott Laboratories (ABT), as well as two micro-cap stocks SandRidge Energy, Inc. (SD) and CompX International Inc. (CIX). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the research reports have been hand-picked from the roughly 70 reports published by our analyst team can see all of today's research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each can read today's AWS here >>> Pre-Markets Climb on Rate Cut VisibilityToday's Featured Research ReportsMeta Platforms' shares have outperformed the Zacks Internet - Software industry over the past year (+39.2% vs. +37.1%). The company is benefiting from steady user growth across all regions, particularly Asia Pacific. Increased engagement for its offerings like Instagram, WhatsApp, Messenger and Facebook has been a major growth driver. META has been leveraging AI to improve the potency of its offerings. These services currently reach more than 3.43 billion people daily. Meta Platforms' growing footprint among young adults, driven by improving recommendations, boosts its competitive prowess. AI usage is making it a popular name among advertisers. This is expected to drive top-line growth. Meta Platforms now expects to invest significantly more over the next few years in developing more advanced models and the largest AI services in the world. However, monetization of these AI services will take considerable time, which is a concern.(You can read the full research report on Meta Platforms here >>>)Shares of Palantir have outperformed the Zacks Internet - Software industry over the year-to-date period (+85% vs. +13%). The company's AI strategy, driven by Foundry, Gotham and AIP platforms, targets government and commercial sectors, enabling real-time insights and operational efficiency. Notable defense projects like Open DAGIR, and AIP boot camps for commercial clients boost customer acquisition. With $5.2 billion in cash, no debt and S&P 500 inclusion, Palantir enjoys strong liquidity, growing revenues and increased investor visibility. However, PLTR's reluctance to pay quarterly dividends is a minus for dividend-seeking investors. Intense competition from tech giants and rising costs amidst a rapidly evolving AI landscape and an elevated valuation also challenge its appeal. (You can read the full research report on Palantir here >>>)Abbott's shares have outperformed the Zacks Medical - Products industry over the past year (+27.8% vs. +8.9%). The company's pipeline is unlocking new growth opportunities, supporting the company's positive momentum and strong growth outlook for 2025. Freestyle Libre, Lingo and Libre Rio CGM devices are on a great the company's next-generation suite of systems, is a key driver in the core lab diagnostics business. Abbott is optimistic about its latest progress with biosimilars and expects this to significantly boost EPD sales, beginning 2025. Within Nutrition, despite softness in international pediatric arm, Abbott is regaining market share banking on strong Adult Nutrition business. Yet, the significant runoff of COVID-19 testing-related sales is hurting Abbott's Diagnostics growth. Headwinds such as tough macro conditions and foreign exchange also adds to the worry. (You can read the full research report on Abbott here >>>)Shares of SandRidge Energy have outperformed the Zacks Oil and Gas - Integrated - U.S. industry over the year-to-date period (+5.3% vs. -1.6%). This microcap company with a market capitalization of $443.18 million has a debt-free balance sheet and $101.1 million cash position back strong self-funding capacity, and $13.6 million in free cash flow in Q1 2025. Adjusted EBITDA jumped 73% to $25.5 million on higher volumes and better gas prices, with gas now 49% of production. Since 2023, $158 million has been returned to shareholders via dividends and buybacks, with $70 million repurchase capacity remaining. Cherokee drilling supports reserve growth, but capital intensity and WTI/gas price volatility pose risks. Heavy back-half completions, cost inflation, and natural gas legacy underutilization limit efficiency. Large NOLs support tax sheltering but rely on consistent profits; Section 382 limits apply. Reserve quality hinges on Cherokee execution as legacy reserves decline. Commodity swings and execution missteps could pressure cash flow and returns despite strong capital discipline.(You can read the full research report on SandRidge Energy here >>>)CompX International's shares have outperformed the Zacks Office Supplies industry over the past year (+18.8% vs. -38%). This microcap company with a market capitalization of $293.43 million has first-quarter 2025 results highlight resilient core operations and expanding profitability. Security Products maintained a stable gross margin (29.8%) despite OEM softness, supported by gains in government and healthcare markets. Marine Components delivered a 24% year-over-year sales increase and a structural margin uplift to 22.3%, driven by fixed cost leverage and a favorable product mix. The company-wide gross margin rose to 30.2%, fueling a 58% surge in operating income. Cash remained strong at $56.1 million, with no debt and improved inventory efficiency. However, risks include negative operating cash flow due to rising receivables, a 29% drop in interest income and tariff-driven raw material inflation. Continued OEM channel weakness and DSO expansion raise caution, but internal execution and margin tailwinds position CompX for an upside in 2025.(You can read the full research report on CompX International here >>>)Other noteworthy reports we are featuring today include Intuit Inc. (INTU), Illinois Tool Works Inc. (ITW) and Veeva Systems Inc. (VEEV).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Expanding AI Usage Drives Meta Platforms' (META) Prospects Modular Sales Tactic Aids Palantir (PLTR), Competition High Solid EPD Prospects, CGM Leadership Boosts Abbott (ABT) Featured Reports Food Equipment Unit Aids Illinois Tool (ITW) Amid Forex WoesPer the Zacks analyst, Illinois Tool is benefitting from its Food Equipment unit, driven by strength in the institutional end markets in North America. However, forex woes are an added concern. Ross' (ROST) Strong Demand Trends Aid Sales, Tariff Woes HurtPer the Zacks analyst, Ross Stores' sales benefits from ongoing strength in consumer demand. But ongoing macroeconomic and geopolitical uncertainty, including tariff woes, raise investor concerns. Investments Aids PG&E Corporation (PCG) Amid Poor SolvencyPer the Zacks analyst, PG&E makes systematic investments to maintain and upgrade the reliability of its infrastructure. Yet its poor financial ratios indicate weak solvency position. Woodward (WWD) Boosted by Aerospace & Industrial StrengthPer the Zacks analyst, Woodward's strong Aerospace and Core Industrial units are driving growth, amid challenges from China's on-highway natural-gas truck market and Aerospace supply-chain issues. Season Pass Aids Vail Resorts (MTN) Amid Weak VisitationPer the Zacks analyst, Vail Resorts benefits from a stable season pass program and offerings such as the Epic Pass, Epic Day Pass, and Epic Australia Pass. However, weak visitation is a concern. AUM Growth Aids Main Street (MAIN), Rising Costs a DragPer the Zacks analyst, Main Street's robust asset under management (AUM) and strong liquidity back growth. However, increased expenses due to expansion may hurt profitability. Immunovant Bets on IMVT-1402 Amid Intense CompetitionPer the Zacks Analyst, IMVT-1402 could become a best-in-class medication for several autoimmune indications. However, significant competition in the market remains a worry. New Upgrades Intuit (INTU) Rides on Product Refresh, Higher SubscriptionsPer the Zacks analyst, Intuit is benefiting from frequent product refreshes, which help it to gain customers. Moreover, increase in subscriptions is driving stable revenue growth for the company. Veeva Systems (VEEV) Gains on Solid R&D, Strategic AlliancesPer the Zacks analyst, Veeva Systems is gaining from strong customer adoption and strategic alliances. Innovation, a solid product portfolio, and a debt-free balance sheet are also fueling growth. Increase in New Insurance Written Aid MGIC Investment (MTG)Per the Zacks analyst, MGIC Investment is poised to grow on higher insurance in force, improved direct premium yield, higher annual persistency, lower claims and a strong capital position. New Downgrades Helmerich & Payne (HP) Risks from Falling U.S. Rig DemandThe Zacks analyst believes that Helmerich & Payne's strong dependence on U.S. drilling puts it at risk of lower rig demand and weaker margins if oil prices continue falling. Campbell's (CPB) Appears Troubled by Elevated Cost InflationPer the Zacks analyst, cost inflation hurt Campbell's gross margin. In Q3 adjusted gross profit margin fell 110 basis points to 30.1%, impacted by cost inflation and supply-chain costs among others. Soft Industrial Demand, Repositioning Ail Ingevity (NGVT)According to the Zacks analyst, Ingevity faces headwinds from weaker industrial demand. Its repositioning measures will also hurt sales in the industrial specialties product line. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illinois Tool Works Inc. (ITW) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuit Inc. (INTU) : Free Stock Analysis Report SandRidge Energy, Inc. (SD) : Free Stock Analysis Report CompX International Inc. (CIX) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report Palantir Technologies Inc. (PLTR) : Free Stock Analysis Report Meta Platforms, Inc. (META) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
Leerink Partners Begins Coverage on ABT
Abbott Laboratories (NYSE:ABT) is one of Best Dividend Stocks to Buy for Dependable Growth. The company is a Dividend King with 53 consecutive years of dividend growth. Its five-year average annual dividend growth rate sits at nearly 11%. It pays a quarterly dividend of $0.59 per share and has a dividend yield of 1.78%, as of June 17. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Leerink Partners has initiated coverage of the medical devices company, assigning it a hold-equivalent rating along with a target price of $143. This target suggests an upside of less than 6% from the stock's closing price on Friday. Although Abbott Laboratories (NYSE:ABT) is recognized for its strong industry position, Leerink's analysts mentioned that they think 'potential upside growth drivers and strong execution' are mostly already reflected in the company's 'stock at current peak valuation levels,' and they do not see any significant near-term catalysts. Abbott Laboratories (NYSE:ABT) recently received positive news from Canada, where the government approved a rapid blood test designed to assist clinicians in evaluating suspected concussions. Although this may not have an immediate significant impact, it's an intriguing product with potential applications, such as at sporting events. Abbott Laboratories (NYSE:ABT) is an international healthcare company that develops, produces, and markets a broad variety of health-related products. The stock has surged by over 16% since the start of 2025. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
Yahoo
4 days ago
- Business
- Yahoo
Leerink Partners Begins Coverage on ABT
Abbott Laboratories (NYSE:ABT) is one of Best Dividend Stocks to Buy for Dependable Growth. The company is a Dividend King with 53 consecutive years of dividend growth. Its five-year average annual dividend growth rate sits at nearly 11%. It pays a quarterly dividend of $0.59 per share and has a dividend yield of 1.78%, as of June 17. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Leerink Partners has initiated coverage of the medical devices company, assigning it a hold-equivalent rating along with a target price of $143. This target suggests an upside of less than 6% from the stock's closing price on Friday. Although Abbott Laboratories (NYSE:ABT) is recognized for its strong industry position, Leerink's analysts mentioned that they think 'potential upside growth drivers and strong execution' are mostly already reflected in the company's 'stock at current peak valuation levels,' and they do not see any significant near-term catalysts. Abbott Laboratories (NYSE:ABT) recently received positive news from Canada, where the government approved a rapid blood test designed to assist clinicians in evaluating suspected concussions. Although this may not have an immediate significant impact, it's an intriguing product with potential applications, such as at sporting events. Abbott Laboratories (NYSE:ABT) is an international healthcare company that develops, produces, and markets a broad variety of health-related products. The stock has surged by over 16% since the start of 2025. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio
Yahoo
5 days ago
- Business
- Yahoo
Abbott, Tandem Diabetes Care Partner For Glucose-Ketone Sensor for Diabetes Management
Abbott Laboratories (NYSE:ABT) is one of the best stocks to buy for beginners now. On June 10, Tandem Diabetes Care Inc. (NASDAQ:TNDM) announced a new agreement with Abbott to develop and commercialize integrated diabetes solutions. The collaboration will combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems, with the aim of providing more comprehensive management options for individuals with diabetes. The Abbott sensor, which is currently under development, will feature combined glucose and ketone sensing technology. The primary goal of the integrated sensor is to help people living with diabetes detect early rises in ketone levels, and thereby enable them to take prompt action and potentially avoid life-threatening diabetic ketoacidosis/DKA. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The President and CEO of Tandem Diabetes Care, John Sheridan, stated that integrating Tandem's advanced insulin delivery systems with Abbott's future dual glucose-ketone sensor has the potential to empower patients with diabetes to make faster, more informed decisions about their health, which would ultimately lead to improved outcomes. Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells health care products worldwide. Tandem Diabetes Care Inc. (NASDAQ:TNDM) designs, develops, and commercializes technology solutions for people living with diabetes. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
11-06-2025
- Business
- Yahoo
Abbott Laboratories (NYSE:ABT) Partners With Tandem To Develop Dual Sensor Diabetes Solutions
Tandem Diabetes Care, Inc. recently announced a significant collaboration with Abbott Laboratories to integrate Abbott's upcoming dual glucose-ketone sensor with Tandem's insulin delivery systems. This and other collaborations, such as the agreement with Sequel Med Tech, align with Abbott's strategic focus on enhancing diabetes care. Abbott's shares rose 3% over the last quarter, aligning closely with broader market trends, which advanced 13% over the past year. The company's robust product approvals and partnerships, alongside positive market sentiment, likely reinforced investor confidence in Abbott's growth trajectory amid generally favorable market conditions. You should learn about the 1 possible red flag we've spotted with Abbott Laboratories. Find companies with promising cash flow potential yet trading below their fair value. The recent collaboration between Tandem Diabetes Care, Inc. and Abbott Laboratories to integrate Abbott's dual glucose-ketone sensor has the potential to enhance Abbott's market positioning in diabetes care. This partnership, along with other strategic agreements, could support revenue growth in Abbott's Diabetes Care segment, though challenges such as tariffs and VBP program impacts in China remain. Abbott's five-year total return, including share price and dividends, stands at 63.31%, showcasing strong longer-term performance, despite some earnings forecast pressure. In the past year, Abbott's shares have risen above the US Medical Equipment industry, which saw a return of 8.2%. This outperformance over a shorter time horizon indicates that investor confidence remains buoyant. However, the expectation of declining earnings over the next three years, with a 10.1% decrease per year, highlights forecast challenges. This contrasts with a forecasted revenue growth of 6.9% annually, which is slower than the broader US market growth rate of 8.6% per year. The current share price of US$133.06 reflects a modest 5.2% discount to the consensus analyst price target of US$140.41, suggesting a perception of fair valuation compared to expected earnings growth and projected revenue increases. Insights from our recent valuation report point to the potential undervaluation of Abbott Laboratories shares in the market. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:ABT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
